Efficacy and safety of topical hirudin (Hirudex): a double-blind, placebo-controlled study
Stamenova PK, Marchetti T, Simeonov I (2001) · European Review for Medical and Pharmacological Sciences · n=60
Perfil del estudio
- Diseño
- single-center, double-blind, placebo-controlled randomized clinical trial of a topical hirudin-containing cream (Hirudex; Hirudo medicinalis extract 280 UI/100g) for acute musculoskeletal bruises (Bulgaria)
- Tamaño de la muestra (n)
- 60
- Intervención
- Hirudex cream containing Hirudo medicinalis extract 280 UI/100g, applied 3-4 times daily for 5 days (15-20 total administrations) (n=30)
- Comparador
- Matching placebo cream applied with identical dosing regimen for 5 days (n=30); double-blinded for both patients and investigators
- Punto final primario
- Improvement in three major efficacy parameters (bruise size, pain, hematoma resolution) at each follow-up visit; overall efficacy assessment by patient and investigator at end of study
- Resultado primario
- Highly statistically and clinically significant improvement in Hirudin group across all three major efficacy parameters at each follow-up visit (p<0.001 vs placebo); both patient-rated and investigator-rated overall efficacy significantly better in Hirudin arm at end of study
- Duración del seguimiento
- 5 days of treatment plus end-of-study assessment
- PMID
- 11863317
Hallazgos clave
- Only published PubMed-indexed double-blind placebo-controlled RCT of a topical leech-derived (Hirudo medicinalis extract) product in PubMed
- Statistically significant benefit for all three efficacy parameters at each follow-up visit (p<0.001)
- Tests a topical cream formulation - distinct from whole-leech therapy - containing 280 UI hirudin per 100g cream
- Bulgarian registration study supporting Hirudex cream for mild-to-moderate bruises with or without hematoma
- Important boundary case for the registry: distinguishes leech-derived pharmaceutical from whole-leech device application
Limitaciones
- Small sample (n=60) limits subgroup analyses
- Single-center Bulgarian trial - generalizability untested in broader populations
- Tests acute bruise/hematoma indication only, not chronic venous insufficiency or other leech-therapy targets
- Cream formulation only - does not generalize to other hirudin delivery routes (injectable lepirudin, etc.)
- Short 5-day treatment period; no long-term follow-up data
Implicaciones clínicas
Stamenova 2001 is important as the only double-blind placebo-controlled RCT in the PubMed-indexed hirudo-related literature, testing a topical hirudin cream formulation for acute bruises. It does not support whole-leech therapy efficacy but does provide proof-of-concept evidence that topical hirudin extract can produce clinical benefit in superficial soft-tissue injury. For clinicians, the trial is a useful reference point when distinguishing whole-leech device application (FDA K040187) from leech-derived pharmaceutical products. The cream is not currently marketed in the US, but the underlying biochemistry (hirudin as a thrombin inhibitor) supports the general mechanistic case for topical anticoagulant formulations in superficial vascular conditions.